GSK reaches agreement to acquire late-stage biopharmaceutical company BELLUS Health
Acquisition further strengthens specialty medicines and respiratory pipeline with camlipixant, a highly selective P2X3 antagonist and potential best-in-class treatment for refractory chronic cough Currently in phase III clinical development with anticipated regulatory approval and launch in 2026 Accretive to adjusted EPS from 2027 with significant sales potential through 2031 LONDON–(BUSINESS WIRE)–GSK plc (LSE/NYSE: GSK) and … [Read more…]
